Report : Europe Organoids Market Forecast to 2030 – Regional Analysis – by Organ Type (Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, and Others), Application (Development of Biology Disease, Pathology of infectious Disease, Regenerative Medicines, Drug Discovery and Personalized Medicine, Drug Toxicity and Efficacy Testing, and Others), Source (Pluripotent Stem Cell and Organ Specific Adult Stem Cell), and Type (Instruments, Consumables, and Services)

At 21.8% CAGR, the Europe Organoids Market is speculated to be worth US$ 4,080.52 million by 2030, says Business Market Insights

According to Business Market Insights research, the Europe organoids market was valued at US$ 842.19 million in 2022 and is expected to reach US$ 4,080.52 million by 2030, registering a CAGR of 21.8% from 2022 to 2030. Focus on drug discovery activities is the critical factor attributed to the Europe organoids market expansion.

The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated to be 356,282. A recent survey by the Hubrecht Institute states that organoids can potentially make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. An increasing number of clinical trials worldwide is expected to drive the demand for advanced medical technologies, including organoid models.

Further, organoids in drug discovery are not limited to just cancer, they are also used in other diseases, such as cystic fibrosis, polycystic kidney disease, microcephaly, and infectious diseases of the gut and airway. For instance, organoids can summarize the properties of an organ, such as organ structure and function. Also, organoids can restore a tissue or organ's original genetic and epigenetic state, making them suitable for gene editing. Various studies have shown positive results of combining CRISPR-Cas9 technology with organoids, which has expanded opportunities for breakthroughs in cystic fibrosis. According to a study ‘CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank,’ published in 2020, a biobank of cystic fibrosis intestinal organoids represented 664 patients, and ~20% of them were theoretically able to efficiently repair nonsense mutations in the cystic fibrosis transmembrane conductor receptor through adenine base editors. Despite a few achievements of gene-edited organoids in some animal models, their efficiency is significantly low, and the success rate is not high. Therefore, it is crucial to research and develop a process for gene-edited organoids' safety, long-term stability, and functionality.

Moreover, the COVID-19 pandemic triggered the need to develop human lung organoid models. For instance, MilliporeSigma developed a 3dGRO Human Lung Organoid Culture System that allows researchers to control, access, and reproduce organ tissue for culturing an organoid model of human lung epithelium that can aid in obtaining positive and successful results during their research. Thus, such innovations are expected to offer more significant growth opportunities for the market growth.

On the contrary, issues related to incorporation of organoids into existing workflows hampers the Europe organoids market.  

Based on organ type, the Europe organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney and others. The intestine segment held 23.2% share of Europe organoids market in 2022, amassing US$ 195.42 million. It is projected to garner US$ 929.64 million by 2030 to expand at 21.5% CAGR during 2022–2030.   

Based on type, the Europe organoids market is segmented into instruments, consumables, and services. The consumables segment held 56.6% share of Europe organoids market in 2022, amassing US$ 476.38 million. It is projected to garner US$ 2,425.74 million by 2030 to expand at 22.6% CAGR during 2022–2030.

Based on application, the Europe organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held 29.4% share of Europe organoids market in 2022, amassing US$ 248.01 million. It is projected to garner US$ 1,257.98 million by 2030 to expand at 22.5% CAGR during 2022–2030.

Based on source, the Europe organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held 72.5% share of Europe organoids market in 2022, amassing US$  610.21 million. It is projected to garner US$  3,049.98 million by 2030 to expand at 22.3% CAGR during 2022–2030.

Based on country, the Europe organoids market has been categorized into the Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 20.8% share of Europe organoids market in 2022. It was assessed at US$   175.38 million in 2022 and is likely to hit US$  893.57 million by 2030, exhibiting a CAGR of 22.6% during 2022–2030.

Key players operating in the Europe organoids market are Cellesce, Definigen, Hubrecht organoid technology, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc, among others.   

  • In Feb 2023, the collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the unmet market need for high-throughput automated cell line culturing and maintenance.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com

Download Free PDF Brochure